Multiscale Model Identifies Improved Schedule for Treatment of Acute Myeloid Leukemia In Vitro With the Mcl‐1 Inhibitor AZD5991

Anticancer efficacy is driven not only by dose but also by frequency and duration of treatment. We describe a multiscale model combining cell cycle, cellular heterogeneity of B‐cell lymphoma 2 family proteins, and pharmacology of AZD5991, a potent small‐molecule inhibitor of myeloid cell leukemia 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Goliaei, Ardeshir, Woods, Haley A., Tron, Adriana E., Belmonte, Matthew A., Secrist, J. Paul, Ferguson, Douglas, Drew, Lisa, Fretland, Adrian J., Aldridge, Bree B., Gibbons, Francis D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577016/
https://www.ncbi.nlm.nih.gov/pubmed/32860732
http://dx.doi.org/10.1002/psp4.12552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7577016/
https://www.ncbi.nlm.nih.gov/pubmed/32860732
http://dx.doi.org/10.1002/psp4.12552

Ejemplares similares